Silence Therapeutics (SLN) Gross Margin (2020 - 2026)
Silence Therapeutics recorded quarterly Gross Margin of 97.39% in Q1 2026, up 50.52% quarter-over-quarter from 64.71% in Q4 2025, and up 3542.0% year-over-year from 2.67% in Q1 2025.
Silence Therapeutics' Gross Margin history runs 7 years deep, the most recent figure standing at 97.39% for Q1 2026.
- In Q1 2026, Gross Margin rose 3542.0% year-over-year to 97.39%; the TTM figure through Mar 2026 stood at 81.84% (up 1456.0% YoY), while the FY2025 annual figure was 61.54%, down 1116.0% from the prior year.
- Gross Margin came in at 97.39% for Q1 2026 at Silence Therapeutics, up from 64.71% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 97.39% in Q1 2026 to a low of 340.87% in Q2 2024.
- A 5-year average of 23.22% and a median of 60.14% in 2023 frame the typical range for Gross Margin.
- On a YoY basis, Gross Margin climbed as much as 2000000000 bps in 2022 and fell as far as 2000000000 bps in 2022.
- Silence Therapeutics' Gross Margin stood at 19.01% in 2022, then surged by 89 bps to 35.87% in 2023, then jumped by 156 bps to 91.95% in 2024, then retreated by 30 bps to 64.71% in 2025, then surged by 51 bps to 97.39% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 97.39%, 64.71%, and 59.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | 97.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.39% |
| Dec 31, 2025 | 64.71% |
| Sep 30, 2025 | 59.75% |
| Jun 30, 2025 | 69.50% |
| Mar 31, 2025 | 61.97% |
| Dec 31, 2024 | 91.95% |
| Sep 30, 2024 | -142.92% |
| Jun 30, 2024 | -340.87% |
| Mar 31, 2024 | 82.16% |
| Dec 31, 2023 | 35.87% |
| Sep 30, 2023 | 42.57% |
| Jun 30, 2023 | 68.90% |
| Mar 31, 2023 | 60.14% |
| Dec 31, 2022 | 19.01% |
| Sep 30, 2022 | 28.98% |
| Jun 30, 2022 | 35.44% |
| Mar 31, 2022 | 60.24% |
| Dec 31, 2021 | -105,067,224.40% |
| Sep 30, 2021 | 34,980,988.59% |
| Jun 30, 2021 | 32.43% |
| Mar 31, 2021 | 51.11% |
| Dec 31, 2020 | 31.34% |
| Sep 30, 2020 | -17,253,521.13% |